Renin-Angiotensin-Aldosterone System Blockade in Diabetes: Role of Direct Renin Inhibitors
- 1 May 2009
- journal article
- review article
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 121 (3) , 33-44
Abstract
Cardiovascular (CV) and renal complications associated with diabetes can be attenuated with antihypertensives that work on the renin-angiotensin-aldosterone system (RAAS),particularly angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and possibly direct renin inhibitors (DRIs). Cardioprotective and renoprotective benefits are independent of the blood pressure-lowering effect of the RAAS inhibitor. Given more complete RAAS blockade, evidence has suggested that the use of ACE inhibitor/ARB combination therapy may provide greater target organ protection. However, recent data have challenged this assumption. Although advances have been made in reducing diabetic nephropathy progression through use of ACE inhibitors and ARBs, improvement in organ protection is needed because diabetes remains the leading cause of end-stage renal disease. Despite the use of these agents in patients with CV disease and diabetes, CV adverse events remain high, suggesting the need for improved outcomes. Newer agents such as DRIs may have the potential to offer similar target organ protection. The first DRI, aliskiren, administered alone or in combination with other RAAS inhibitors, has been shown to confer renoprotective and cardioprotective benefits in human and animal studies that have measured surrogate endpoints. An ongoing outcomes study (Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints [ALTITUDE]), which is assessing renal and CV morbidity and mortality, will further define whether aliskiren provides additional benefits beyond RAAS inhibition and lowering of blood pressure.Keywords
This publication has 98 references indexed in Scilit:
- Economic Costs of Diabetes in the U.S. in 2007Diabetes Care, 2008
- Long-term safety, tolerability and efficacy of aliskiren in combination with valsartan in patients with hypertension: a 6-month interim analysisCurrent Medical Research and Opinion, 2008
- Standards of Medical Care in Diabetes—2008Diabetes Care, 2008
- Aliskiren Exhibits Similar Pharmacokinetics in Healthy Volunteers and Patients with Type 2 Diabetes MellitusClinical Pharmacokinetics, 2006
- Molecular and cellular mechanisms in vascular injury in hypertension: role of angiotensin II – editorial reviewCurrent Opinion in Nephrology and Hypertension, 2005
- Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)Kidney International, 2003
- Effect of Captopril on Heavy Proteinuria in Azotemic DiabeticsNew England Journal of Medicine, 1985
- Increased Plasma Inactive Renin in Diabetes MellitusNew England Journal of Medicine, 1985
- Microalbuminuria Predicts Clinical Proteinuria and Early Mortality in Maturity-Onset DiabetesNew England Journal of Medicine, 1984
- Increased Incidence of Retinopathy in Diabetics with Elevated Blood PressureNew England Journal of Medicine, 1980